Clinical trials: Relapsing Remitting Multiple Sclerosis RRMS
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.
- Trial name
- SKORE (NCT01075880)
- Testing
- Rebif (Interferon beta-1a)
- Where
- 13 sites in Czechia
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
The purpose of this study is to evaluate whether the use of ACTH in addition to Avonex is effective in the treatment of relapsing remitting multiple sclerosis.
- Trial name
- ACTH (NCT00986960)
- Testing
- repository corticotropin injection, Saline
- Where
- United States
- Sponsor
- University at Buffalo
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05242133
- Testing
- Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe
- Where
- Iran
- Volunteers
- 168 people
- Sponsor
- Cinnagen
Multiple Sclerosis, Relapsing-Remitting
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
The first major objective of this pilot trial is to demonstrate that it is possible to study myelin repair in relapsing-remitting multiple sclerosis (RRMS) patients with enhancing lesions on MRI by using advanced imaging…
- Trial name
- NCT02493049
- Testing
- Domperidone
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- University of Calgary